Recent Findings on the Role of Micrornas in Genetic Kidney Diseases Publisher Pubmed



Askari H¹ ; Raeisabdollahi E^{2, 3} ; Abazari MF⁴ ; Akrami H¹ ; Vakili S⁵ ; Savardashtaki A^{5, 6} ; Tajbakhsh A⁷ ; Sanadgol N⁸ ; Azarnezhad A⁹ ; Rahmati L¹ ; Abdullahi PR¹⁰ ; Zare Karizi S¹¹ ; Safarpour AR¹
Source: Molecular Biology Reports Published:2022

Abstract

Background: MicroRNAs (miRNAs) are non-coding, endogenous, single-stranded, small (21–25 nucleotides) RNAs. Various target genes at the post-transcriptional stage are modulated by miRNAs that are involved in the regulation of a variety of biological processes such as embryonic development, differentiation, proliferation, apoptosis, inflammation, and metabolic homeostasis. Abnormal miRNA expression is strongly associated with the pathogenesis of multiple common human diseases including cardiovascular diseases, cancer, hepatitis, and metabolic diseases. Methods and results: Various signaling pathways including transforming growth factor-β, apoptosis, and Wnt signaling pathways have also been characterized to play an essential role in kidney diseases. Most importantly, miRNA-targeted pharmaceutical manipulation has represented a promising new therapeutic approach against kidney diseases. Furthermore, miRNAs such as miR-30e-5p, miR-98-5p, miR-30d-5p, miR-30a-5p, miR-194-5p, and miR-192-5p may be potentially employed as biomarkers for various human kidney diseases. Conclusions: A significant correlation has also been found between some miRNAs and the clinical markers of renal function like baseline estimated glomerular filtration rate (eGFR). Classification of miRNAs in different genetic renal disorders may promote discoveries in developing innovative therapeutic interventions and treatment tools. Herein, the recent advances in miRNAs associated with renal pathogenesis, emphasizing genetic kidney diseases and development, have been summarized. © 2022, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.